Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18808392 | TREATMENT OF IMMUNOSUPPRESSED SUBJECTS | August 2024 | March 2025 | Allow | 7 | 1 | 0 | No | No |
| 18782666 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS | July 2024 | February 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18783305 | HYDROGEL FORMULATIONS AND METHODS AND DEVICES FOR ADMINISTRATION OF THE SAME | July 2024 | December 2024 | Allow | 5 | 0 | 0 | No | No |
| 18662516 | METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS | May 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18619502 | COCHLEATES MADE WITH SOY PHOSPHATIDYLSERINE | March 2024 | May 2025 | Allow | 13 | 1 | 0 | No | No |
| 18423548 | BACTERICIDAL AND VIRUCIDAL PHARMACEUTICAL COMPOSITION | January 2024 | August 2024 | Allow | 7 | 0 | 0 | No | No |
| 18416548 | Compositions for Treatment of Attention Deficit Hyperactivity Disorder | January 2024 | April 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18406605 | SOIL APPLICATION OF CROP PROTECTION AGENTS | January 2024 | March 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18398070 | Prophylactic and Therapeutic Agents for Upper Respiratory Tract Infections Caused by Influenza and Other Enveloped Viruses | December 2023 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18530533 | LEAVE-ON ORAL CARE COMPOSITIONS | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18519662 | METHOD OF MAKING GOLD NANOPARTICLES CAPPED WITH RESEDA ARABICA EXTRACT AND TREATMENT METHOD USING THE SAME | November 2023 | February 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18517798 | COMPOSITION FOR PROMOTING HAIR GROWTH AND IMPROVING, PREVENTING, OR TREATING HAIR LOSS CONTAINING 2'-FUCOSYLLACTOSE AS AN ACTIVE INGREDIENT | November 2023 | July 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18287463 | PREPARATION METHOD AND APPLICATION OF BIOMIMETIC NANO-PROTECTANT FOR DETOXIFYING DOX-INDUCED CARDIAC AND SYSTEMIC TOXICITY | October 2023 | July 2024 | Allow | 9 | 1 | 0 | Yes | No |
| 18470691 | HIGH-PURITY STEVIOL GLYCOSIDES | September 2023 | April 2025 | Allow | 19 | 2 | 0 | No | No |
| 18448578 | CERAMIDE-LIKE LIPID-BASED DELIVERY VEHICLES AND USES THEREOF | August 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18365370 | METHODS OF PREPARING STEVIOL GLYCOSIDES AND USES OF THE SAME | August 2023 | April 2024 | Allow | 9 | 1 | 0 | No | No |
| 18361630 | POLY(AMINE-CO-ESTER) POLYMERS AND POLYPLEXES WITH MODIFIED END GROUPS AND METHODS OF USE THEREOF | July 2023 | February 2024 | Allow | 7 | 0 | 0 | No | No |
| 18338052 | COPPER ION COMPOSITIONS AND METHODS OF TREATMENT FOR CONDITIONS CAUSED BY CORONAVIRUS AND INFLUENZA | June 2023 | February 2025 | Allow | 20 | 2 | 0 | No | No |
| 18326293 | TREATMENT OF IMMUNOSUPPRESSED SUBJECTS | May 2023 | July 2024 | Allow | 13 | 3 | 0 | Yes | No |
| 18322744 | Nucleic Acid-Based Therapy of Muscular Dystrophies | May 2023 | October 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18136553 | QUAT-FREE POWDERED DISINFECTANT/SANITIZER | April 2023 | December 2024 | Allow | 20 | 2 | 0 | No | No |
| 18129073 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | March 2023 | September 2024 | Allow | 17 | 1 | 1 | No | No |
| 18170229 | Nanoparticle/Peptide Method of Blocking Potassium Channels | February 2023 | December 2023 | Allow | 10 | 0 | 0 | No | No |
| 18165398 | Oral Care Product and Methods of Use and Manufacture Thereof | February 2023 | September 2024 | Allow | 19 | 2 | 0 | No | No |
| 18101974 | Method of Treating Hair Loss and Formulation for Treatment | January 2023 | September 2024 | Allow | 19 | 1 | 0 | No | No |
| 18083786 | Natural Preservatives and Antimicrobial Agents, Including Compositions Thereof | December 2022 | July 2024 | Allow | 19 | 1 | 0 | No | No |
| 17973753 | Risk Mitigation of Infectious Disease Transmission from Incidental and Intimate Contact Using Atomic Scale Molecular Disruption and Biocidal Halo-fullerenes Delivered via Topical, Flushing and Enteral Mechanisms | October 2022 | February 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 17907029 | A METHOD OF ADMINISTERING A NANOPARTICLE | September 2022 | May 2025 | Allow | 31 | 0 | 0 | No | No |
| 17902617 | Oral Care Compositions and Methods | September 2022 | June 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17897907 | FILAMENTS COMPRISING AN ACTIVE AGENT NONWOVEN WEBS AND METHODS FOR MAKING SAME | August 2022 | March 2024 | Allow | 18 | 1 | 0 | No | No |
| 17884241 | 3D PRINTING BIO GEL AND METHOD OF USE | August 2022 | May 2025 | Allow | 33 | 2 | 0 | Yes | No |
| 17883491 | METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS | August 2022 | February 2024 | Allow | 18 | 1 | 0 | No | No |
| 17852892 | CANNABINOID CHEWING GUM WITH HIGH INTENSITY SWEETENERS | June 2022 | December 2024 | Allow | 29 | 3 | 0 | No | No |
| 17847604 | AQUEOUS COSMETIC COMPOSITIONS CONTAINING PELARGONIC ACID ESTERS | June 2022 | January 2024 | Allow | 19 | 1 | 0 | No | No |
| 17745138 | D GLUTAMATE POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | May 2022 | February 2025 | Allow | 33 | 2 | 1 | No | No |
| 17776643 | CARBAZATE-ACTIVATED POLYVINYL ALCOHOL (PVAC) AS A POLYMER-BASED ANTITUMORAL AGENT | May 2022 | April 2025 | Allow | 35 | 1 | 0 | No | No |
| 17713257 | COMPOSITION FOR HAIR REGENERATION COMPRISING MACROPHAGE-DERIVED EXTRACELLULAR VESICLE MIMETICS | April 2022 | March 2025 | Allow | 36 | 2 | 1 | No | No |
| 17711523 | FORMULATION FOR NASAL DELIVERY OF CANNABINOIDS | April 2022 | July 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17711643 | QUAT-FREE POWDERED DISINFECTANT/SANITIZER | April 2022 | October 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17766060 | W/O/W EMULSION COMPOSITION | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17641651 | ULTRASOUND PHANTOM | March 2022 | May 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17689314 | BRANCHED POLY(-AMINO ESTERS) FOR THE DELIVERY OF NUCLEIC ACIDS | March 2022 | June 2025 | Allow | 39 | 1 | 1 | No | No |
| 17679192 | CHEWABLE PHARMACEUTICAL DOSAGE FORMS | February 2022 | April 2025 | Allow | 38 | 1 | 0 | No | No |
| 17675664 | BAKUCHIOL COMPOSITIONS FOR TREATMENT OF POST INFLAMMATORY HYPERPIGMENTATION | February 2022 | October 2023 | Allow | 20 | 1 | 0 | No | No |
| 17675931 | CAPSID THERAPY | February 2022 | January 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17666538 | ANTITUMOR APPLICATION OF POLYSACCHARIDE CARBON NANOGELS | February 2022 | January 2025 | Allow | 36 | 1 | 0 | No | No |
| 17632179 | Compositions and Related Methods | February 2022 | March 2025 | Allow | 38 | 1 | 0 | No | No |
| 17565885 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | December 2021 | April 2024 | Allow | 28 | 1 | 0 | No | No |
| 17562871 | HYPOHALOUS ACIDS FOR TREATING INFLAMMATORY DISEASES AND INHIBITING GROWTH OF MALIGNANCIES | December 2021 | October 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17557524 | Compositions for Treatment of Attention Deficit Hyperactivity Disorder | December 2021 | October 2023 | Allow | 22 | 2 | 0 | Yes | Yes |
| 17557476 | Compositions for Treatment of Attention Deficit Hyperactivity Disorder | December 2021 | April 2024 | Abandon | 27 | 4 | 0 | No | No |
| 17554668 | LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE | December 2021 | June 2022 | Allow | 6 | 0 | 0 | Yes | No |
| 17552660 | COMPOSITIONS, METHODS, KITS AND SYSTEMS FOR CANCER TREATMENT AND METABOLIC INTERVENTION THERAPY | December 2021 | June 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17544182 | POLYGLUTAMATED PEMETREXED AND USES THEREOF | December 2021 | September 2024 | Allow | 33 | 2 | 0 | No | No |
| 17544196 | ALPHA AND GAMMA-D POLYGLUTAMATED PEMETREXED ANTIFOLATES AND USES THEREOF | December 2021 | August 2024 | Allow | 33 | 1 | 0 | No | No |
| 17544191 | ALPHA POLYGLUTAMATED PEMETREXED AND USES THEREOF | December 2021 | August 2024 | Allow | 32 | 1 | 0 | No | No |
| 17608648 | DEODORANT COMPOSITION | November 2021 | November 2024 | Allow | 37 | 2 | 0 | No | No |
| 17513484 | BIOLOGICAL HAIR SHAPE CHANGE COMPOSITION AND KIT, AND METHOD FOR CHANGING HAIR SHAPE | October 2021 | October 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17605860 | METHOD FOR MANUFACTURING PHARMACEUTICAL PREPARATION | October 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17602856 | TOLEROGENIC ARTIFICIAL ANTIGEN-PRESENTING CELLS | October 2021 | July 2024 | Allow | 33 | 1 | 1 | No | No |
| 17482807 | ANTI-ADHERENT COMPOSITIONS AND METHODS OF INHIBITING THE ADHERENCE OF MICROBES TO A SURFACE | September 2021 | December 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17480455 | METHODS OF PREPARING STEVIOL GLYCOSIDES AND USES OF THE SAME | September 2021 | May 2023 | Allow | 19 | 0 | 0 | No | No |
| 17479358 | MEDICAL CEMENT COMPOSITION | September 2021 | July 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17593436 | CAPSULES AND CAPSULE COATINGS FOR GASTRIC RESIDENCE DOSAGE FORMS | September 2021 | April 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17478441 | ANTIVIRAL COMPOSITIONS AND METHODS | September 2021 | April 2025 | Allow | 43 | 5 | 0 | No | No |
| 17438691 | PEST CONTROL MATERIAL USING ENTOMOPARASITIC MICROBE AND PEST CONTROL METHOD USING SAME | September 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17468604 | COMPOSITION FOR USE IN THE TREATMENT OF LESIONS IN THE MUCOSA BY MEANS OF ENDOSCOPIC RESECTION | September 2021 | November 2024 | Abandon | 39 | 3 | 1 | No | No |
| 17467427 | DRUG-LOADED NANOFIBER MEMBRANE, METHOD FOR PREPARING THE SAME, AND APPLICATION THEREOF | September 2021 | September 2024 | Allow | 37 | 1 | 0 | No | No |
| 17436542 | Preservative Compositions and Methods of Use Thereof | September 2021 | November 2024 | Allow | 38 | 1 | 0 | No | No |
| 17465034 | DRUG DELIVERY SYSTEMS CONTAINING OXIDIZED CHOLESTEROLS | September 2021 | February 2024 | Allow | 30 | 1 | 1 | No | No |
| 17464913 | HIGH-PURITY STEVIOL GLYCOSIDES | September 2021 | October 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17406892 | MUSK COMPOSITIONS AND METHODS OF USE THEREOF | August 2021 | August 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17432333 | SKIN ENGAGING MEMBER FOR RAZOR CARTRIDGE COMPRISING SKIN ACTIVE INGREDIENT | August 2021 | March 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17428512 | TEMPLATED ANTIMICROBIAL MICROGELS AND METHODS OF MAKING AND USING THE SAME | August 2021 | October 2024 | Allow | 39 | 1 | 0 | No | No |
| 17394103 | FORMULATIONS FOR TREATING ACID REFLUX COMPRISING SODIUM ALGINATE | August 2021 | October 2023 | Allow | 26 | 2 | 0 | Yes | No |
| 17392294 | METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION | August 2021 | March 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17391871 | USE OF CRUDE CORN OIL FOR REDUCING PHYTOTOXICITY OF PESTICIDES AND PLANT WASHES AND ENHANCING OVERALL PLANT HEALTH | August 2021 | March 2023 | Allow | 19 | 0 | 1 | No | No |
| 17380859 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | July 2021 | August 2022 | Allow | 13 | 1 | 1 | No | No |
| 17379019 | Rinseable Multi-Phase Compositions | July 2021 | November 2022 | Allow | 16 | 0 | 0 | No | No |
| 17375703 | INDOLE DERIVATIVES FOR BIOFILM DISRUPTION AND INHIBITION | July 2021 | August 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17374287 | PEGYLATED PEPTIDE AMPHIPHILE NANOFIBERS AND METHODS OF USE | July 2021 | October 2023 | Allow | 27 | 1 | 0 | No | No |
| 17366762 | HYDROGELS AND METHOD OF MAKING THE SAME | July 2021 | May 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17363821 | PHOTONIC STRUCTURE FOR DYNAMIC EXPRESSION OF COLORS AND EFFECTS | June 2021 | February 2025 | Allow | 43 | 3 | 1 | No | No |
| 17350955 | Novel Methods | June 2021 | November 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17309641 | INSECTICIDAL FORMULATION FOR VECTOR AND PEST CONTROL WITH INCREASED CONTACT EFFICACY | June 2021 | December 2024 | Allow | 42 | 1 | 1 | No | No |
| 17303981 | UPCONVERSION NANOPARTICLE PEPTIDE CONJUGATES | June 2021 | November 2023 | Allow | 29 | 1 | 1 | No | No |
| 17340612 | INSECT ATTRACTANT AND KILLING SYSTEM | June 2021 | August 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17309551 | EMULSIFYING COMPOSITION COMPRISING A WATER-IN-OIL EMULSIFIER AND A CYCLODEXTRIN OF SELECTED PARTICLE SIZE, CAPABLE OF PROVIDING AN OIL-IN-WATER EMULSION WITH IMPROVED SENSORY EFFECTS FOR COSMETIC USE | June 2021 | November 2024 | Allow | 41 | 1 | 1 | No | No |
| 17298886 | DEVICES AND METHODS FOR TREATING TISSUES, INCLUDING IRRADIATED TISSUES | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17303409 | BIOCIDAL COMPOSITIONS WITH HYDRONIUM ION SOURCES FOR BIOFILM CONTROL | May 2021 | August 2024 | Allow | 38 | 5 | 0 | Yes | No |
| 17332865 | COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION | May 2021 | April 2024 | Allow | 35 | 1 | 1 | No | No |
| 17328303 | TOPICAL SKIN FORMULATIONS AND WOUND CARE PRODUCTS WITH INTEGRATED CBD DELIVERY MECHANISMS | May 2021 | May 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17328354 | TOPICAL SKIN FORMULATIONS AND WOUND CARE PRODUCTS WITH INTEGRATED CBD DELIVERY MECHANISMS FOR SKIN REJUVENATION | May 2021 | June 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17320883 | COMPOSITE COMPRISING TITANIUM DIOXIDE AND POLYANILINE | May 2021 | July 2023 | Allow | 26 | 1 | 0 | No | No |
| 17313429 | METHOD FOR PREVENTION AND REDUCTION OF SKIN STASIS WITH COMPOSITIONS AND MATERIALS COMPRISING COPPER COMPOUNDS | May 2021 | July 2024 | Allow | 38 | 1 | 1 | No | No |
| 17290201 | COMPOSITION OF ACTIVE INGREDIENTS, FOR CARE OF HUMAN HAIR | April 2021 | June 2025 | Abandon | 50 | 3 | 0 | No | No |
| 17290213 | COMPOSITION OF ACTIVE INGREDIENTS, FOR IMPROVING DEPOSITION OF ANTIOXIDANTS | April 2021 | December 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17290207 | COSMETIC PRODUCT FOR TREATING A KERATIN MATERIAL HAVING ANTI-POLLUTION EFFECTS | April 2021 | February 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17241046 | UNEXPECTEDLY ENHANCED PIGMENTS COMPOSITIONS AND PROCESSES | April 2021 | January 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17239142 | METHODS OF USING IRON-FREE SUPPLEMENTS TO ENHANCE CYTOPROTECTION AGAINST ANEMIA IN HUMANS | April 2021 | February 2023 | Abandon | 22 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COHEN, MICHAEL P.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner COHEN, MICHAEL P works in Art Unit 1612 and has examined 849 patent applications in our dataset. With an allowance rate of 58.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.
Examiner COHEN, MICHAEL P's allowance rate of 58.8% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by COHEN, MICHAEL P receive 2.12 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by COHEN, MICHAEL P is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +27.5% benefit to allowance rate for applications examined by COHEN, MICHAEL P. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.7% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 28.1% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 64.3% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 55.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 55.9% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 67% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.